

# society of urologic oncology

Society of Urologic Oncology: Advancing Cancer Care Through Collaboration and Innovation

**society of urologic oncology** plays a pivotal role in shaping the landscape of cancer treatment related to the urinary tract and male reproductive organs. As a specialized organization, it brings together clinicians, researchers, and healthcare professionals dedicated to improving outcomes for patients with urologic cancers such as prostate, bladder, kidney, and testicular cancers. The society's commitment to education, research, and advocacy fosters a community where knowledge and innovation thrive, ultimately benefiting both practitioners and patients alike.

## Understanding the Society of Urologic Oncology

The society of urologic oncology is more than just a professional association; it serves as a hub for multidisciplinary collaboration, cutting-edge research, and clinical excellence. Founded with the mission to advance the science and practice of urologic oncology, this society promotes the exchange of ideas among urologists, oncologists, radiologists, pathologists, and other healthcare providers involved in cancer care.

One of the core strengths of the society lies in its ability to bridge gaps between various specialties. By fostering an environment where experts from diverse backgrounds converge, the society enhances comprehensive cancer care that addresses every facet of patient management – from diagnosis to treatment and survivorship.

## The Role of Education and Training

A cornerstone of the society of urologic oncology's work is education. Through annual meetings, workshops, and webinars, the society provides ongoing professional development for its members. These educational opportunities cover the latest advances in surgical techniques, systemic therapies, imaging technologies, and molecular diagnostics.

Training programs supported by the society emphasize evidence-based approaches and encourage young clinicians to pursue subspecialty expertise in urologic cancers. The society's mentorship initiatives also enable early-career professionals to connect with seasoned experts, fostering a culture of continuous learning and skill enhancement.

# **Research and Innovation Driven by the Society of Urologic Oncology**

Research is the lifeblood of progress in cancer care, and the society of urologic oncology is deeply invested in promoting and disseminating groundbreaking studies. By organizing research forums and providing grants, the society accelerates investigations into novel therapies, biomarkers, and surgical innovations that promise to transform patient outcomes.

A significant focus area includes the development of personalized medicine approaches. The society encourages research into genetic profiling and targeted treatments, recognizing that tailoring therapy to individual tumor characteristics can improve efficacy and reduce side effects.

## **Clinical Trials and Collaborative Studies**

One of the notable contributions of the society is its facilitation of multi-institutional clinical trials. These studies are critical for evaluating new drugs, immunotherapies, and minimally invasive surgical methods. The society's network enables rapid patient recruitment and data sharing, which enhances the quality and impact of clinical research.

Members are often at the forefront of trials exploring cutting-edge treatments for prostate cancer, including novel androgen receptor inhibitors, as well as advancements in immunotherapy for bladder cancer. This collaborative research model ensures that the latest innovations reach clinical practice sooner.

## **Advocacy and Patient-Centered Care**

Beyond research and education, the society of urologic oncology champions patient advocacy and public awareness. By working closely with patient organizations and policymakers, the society helps shape health policies that improve access to quality cancer care.

## **Improving Access and Support Services**

Efforts to reduce disparities in cancer treatment are central to the society's advocacy work. This includes promoting equitable access to screening, diagnostics, and advanced therapies across diverse populations. The society also emphasizes the importance of psychosocial support and survivorship programs, recognizing that cancer care extends beyond the clinical setting.

## **Raising Awareness and Early Detection**

Early detection of urologic cancers significantly improves prognosis, and the society actively supports campaigns to educate the public and healthcare providers about risk factors and screening guidelines. By enhancing awareness, the society contributes to earlier diagnoses and better patient outcomes.

## **The Impact of the Society of Urologic Oncology on Clinical Practice**

The society's influence permeates daily clinical practice through its development of clinical guidelines and best practice recommendations. These guidelines help standardize care, ensuring that patients receive treatments based on the latest scientific evidence.

## **Guidelines and Protocols**

Members of the society often participate in drafting consensus statements and treatment protocols that address complex clinical scenarios. For example, guidelines on the management of localized versus metastatic prostate cancer provide physicians with clear pathways for patient care.

## **Embracing Technological Advances**

The society also promotes the integration of new technologies such as robotic-assisted surgery, advanced imaging modalities, and molecular diagnostics. By endorsing these innovations, the society helps clinicians adopt tools that enhance precision and reduce complications.

## **Networking and Professional Growth Opportunities**

Membership in the society of urologic oncology offers unparalleled opportunities for networking and career advancement. Annual conferences feature keynote speakers, poster presentations, and interactive sessions that facilitate knowledge exchange and professional connections.

## **Building a Collaborative Community**

The society fosters a sense of community among members, encouraging collaboration on research projects, clinical initiatives, and educational programs. This network often leads to lifelong partnerships and mentorships that enrich professional experiences.

## **Recognition and Awards**

The society also recognizes outstanding contributions through awards and honors, motivating members to excel in research, clinical care, and education. These accolades highlight the importance of innovation and dedication within the field.

## **Looking Ahead: The Future of the Society of Urologic Oncology**

As medicine evolves, the society of urologic oncology remains committed to adapting and leading in the fight against urologic cancers. Emerging trends such as artificial intelligence in diagnostics, liquid biopsies, and novel immunotherapies will likely be key areas of focus.

The society's continued emphasis on multidisciplinary collaboration, patient-centered approaches, and cutting-edge research ensures that it will remain a cornerstone of urologic oncology for years to come. By empowering clinicians and researchers, the society ultimately enhances the quality of life for countless patients facing urologic cancers.

## **Frequently Asked Questions**

### **What is the Society of Urologic Oncology (SUO)?**

The Society of Urologic Oncology (SUO) is a professional organization dedicated to advancing the science and practice of urologic oncology through research, education, and multidisciplinary collaboration.

### **Who can become a member of the Society of Urologic Oncology?**

Membership is typically open to urologists, medical oncologists, radiation oncologists, pathologists, and other healthcare professionals specializing in urologic cancers.

## **What are the main goals of the Society of Urologic Oncology?**

The SUO aims to promote research, education, and clinical excellence in the diagnosis and treatment of urologic cancers, including prostate, bladder, kidney, and testicular cancers.

## **Does the Society of Urologic Oncology offer educational resources or training?**

Yes, the SUO provides various educational resources, including conferences, workshops, webinars, and fellowship training programs to support professional development in urologic oncology.

## **When and where is the annual meeting of the Society of Urologic Oncology held?**

The SUO annual meeting is typically held each year in the United States, with the location varying annually; it features the latest research and clinical advances in urologic oncology.

## **How does the Society of Urologic Oncology contribute to research?**

The SUO supports research by facilitating clinical trials, providing grants and funding opportunities, and fostering collaboration among researchers and clinicians in the field.

## **What types of cancers are primarily focused on by the Society of Urologic Oncology?**

The SUO primarily focuses on cancers of the urinary tract and male reproductive organs, including prostate cancer, bladder cancer, kidney cancer, testicular cancer, and penile cancer.

## **How can patients benefit from the Society of Urologic Oncology?**

Patients benefit indirectly through the SUO's efforts to improve clinical care standards, promote cutting-edge research, and provide education to healthcare providers specializing in urologic cancers.

## **Are there any publications associated with the Society of Urologic Oncology?**

While the SUO itself does not publish its own journal, it frequently

collaborates with major urology and oncology journals and disseminates research findings presented at its meetings.

## **How can healthcare professionals stay updated with the Society of Urologic Oncology's activities?**

Professionals can stay informed by joining the SUO, subscribing to newsletters, attending annual meetings, participating in webinars, and following the society on social media platforms.

## **Additional Resources**

Society of Urologic Oncology: Advancing the Frontiers of Cancer Care in Urology

**society of urologic oncology** stands as a pivotal organization dedicated to the advancement of research, education, and clinical practice related to cancers of the genitourinary tract. Founded with the aim of fostering collaboration among urologists, oncologists, pathologists, radiologists, and researchers, the society plays a critical role in shaping the future of urologic cancer management. In an era where precision medicine and multidisciplinary approaches are increasingly vital, the Society of Urologic Oncology (SUO) has emerged as a beacon for innovation, advocacy, and professional development within this specialized field.

## **The Role and Mission of the Society of Urologic Oncology**

The Society of Urologic Oncology's mission centers on improving patient outcomes through the promotion of scientific exchange, clinical excellence, and cutting-edge research. Unlike general urology associations, the SUO focuses exclusively on malignancies such as prostate, bladder, kidney, testicular, and penile cancers. This specialization allows the society to address the complex challenges inherent in diagnosing, treating, and monitoring urologic cancers, which often require nuanced approaches combining surgery, systemic therapies, and emerging modalities like immunotherapy and targeted treatments.

By bringing together a multidisciplinary membership, the SUO fosters a collaborative environment that bridges gaps between basic science discoveries and clinical application. The society's conferences, workshops, and publications serve as essential platforms where novel techniques, clinical trial data, and evolving standards of care are shared among professionals dedicated to urologic oncology.

## **Educational Initiatives and Professional Development**

One of the cornerstone endeavors of the Society of Urologic Oncology is its commitment to education. The SUO organizes an annual meeting that attracts hundreds of specialists worldwide, providing a forum for presenting groundbreaking research and discussing challenging clinical cases. These meetings often feature keynote lectures, panel discussions, and hands-on workshops designed to enhance surgical skills and familiarize attendees with the latest diagnostic tools.

Beyond conferences, the society offers fellowship programs aimed at training the next generation of urologic oncologists. These fellowships provide intensive exposure to complex cancer cases, multidisciplinary tumor boards, and research opportunities, equipping trainees with the expertise necessary to excel in academic or clinical settings. Additionally, the SUO promotes continuing medical education (CME) through webinars and online resources that keep members abreast of rapidly evolving therapeutic landscapes.

## **Research and Innovation: Driving Cancer Care Forward**

Research is at the heart of the Society of Urologic Oncology's impact on the field. The society actively supports clinical trials and translational research initiatives that seek to improve early detection, risk stratification, and treatment modalities. For example, the SUO endorses studies exploring novel biomarkers for prostate cancer aggressiveness or investigations into minimally invasive surgical techniques for renal tumors.

Moreover, the society's influence extends to policy advocacy, where it champions funding for urologic cancer research and promotes regulatory frameworks that facilitate patient access to innovative therapies. By fostering partnerships between academic institutions, industry stakeholders, and government agencies, the SUO helps accelerate the pace at which scientific breakthroughs reach clinical practice.

## **Membership and Collaborative Networks**

The Society of Urologic Oncology boasts a diverse membership comprising urologic surgeons, medical and radiation oncologists, pathologists, radiologists, scientists, and allied health professionals. This multidisciplinary approach is integral to tackling the multifaceted nature of urologic cancers, which often require coordinated treatment plans involving surgery, chemotherapy, radiation, and emerging immunotherapies.

Membership benefits include access to exclusive research publications, networking opportunities, mentorship programs, and eligibility for leadership roles within the society's committees. These committees focus on various

aspects such as clinical practice guidelines, research priorities, and educational content development, ensuring that the society remains responsive to the evolving needs of its members and the broader medical community.

## **Global Impact and Outreach**

While rooted primarily in North America, the influence of the Society of Urologic Oncology extends globally through collaborative initiatives and partnerships with international urologic and oncologic societies. The SUO promotes global health by supporting educational programs and research in underserved regions and encouraging the exchange of knowledge across geographic boundaries.

Such global outreach efforts are particularly important given the rising incidence of urologic cancers worldwide and disparities in access to quality care. By advocating for standardized treatment protocols and facilitating international clinical trials, the society contributes to improving outcomes for patients regardless of their location.

## **Challenges and Opportunities in Urologic Oncology**

Despite significant advancements, the field of urologic oncology faces ongoing challenges that the Society of Urologic Oncology actively seeks to address. One major hurdle is the heterogeneity of urologic cancers, which complicates diagnosis and necessitates personalized treatment strategies. For instance, prostate cancer ranges from indolent to highly aggressive forms, requiring precise tools to differentiate and tailor interventions.

The SUO supports research into molecular profiling and genetic testing that can refine risk assessment and guide therapy decisions. Additionally, integrating emerging technologies such as artificial intelligence (AI) and machine learning into diagnostic imaging and pathology represents a promising frontier championed by the society's research committees.

Furthermore, balancing the benefits and risks of treatment—such as the potential side effects of radical prostatectomy or bladder removal—remains a critical area of focus. The society encourages the development of less invasive techniques and emphasizes quality-of-life outcomes alongside survival metrics.

## **Advocacy and Policy Influence**

The Society of Urologic Oncology also plays an active role in health policy



and advocacy, recognizing that systemic factors significantly impact cancer care delivery. The society engages with policymakers to promote funding for urologic cancer research, enhance screening programs, and improve patient access to novel therapies.

By collaborating with patient advocacy groups and professional organizations, the SUO strives to raise public awareness about urologic cancers, reduce stigma, and encourage early detection. Such initiatives not only facilitate better clinical outcomes but also empower patients and caregivers through education and support networks.

## **Resources and Publications**

To support its mission, the Society of Urologic Oncology produces a range of scholarly materials, including clinical guidelines, consensus statements, and position papers that influence practice standards worldwide. Its members contribute to leading journals in urologic oncology and related disciplines, disseminating high-impact research findings.

The society's website serves as a hub for educational content, conference information, and tools for clinical decision-making. These resources are invaluable for healthcare professionals seeking to stay informed about the latest evidence-based approaches to managing urologic malignancies.

In addition, the SUO encourages collaborative data sharing and registries that facilitate large-scale research and quality improvement initiatives. By leveraging collective expertise and clinical data, these efforts help identify trends, optimize treatment algorithms, and ultimately enhance patient care.

The Society of Urologic Oncology remains a cornerstone institution in the landscape of cancer care related to the urinary tract and male reproductive organs. Through its dedication to education, research, and advocacy, the society not only advances the science of urologic oncology but also fosters a community committed to improving the lives of patients affected by these complex diseases. As the field continues to evolve with technological and therapeutic innovations, the SUO's role as a leader and collaborator will be instrumental in shaping the future of urologic cancer management.

## **Society Of Urologic Oncology**

Find other PDF articles:

<https://old.rga.ca/archive-th-025/Book?dataid=UXq37-7585&title=bailey-slab-roller-manual.pdf>

**society of urologic oncology:** *Proceedings: Annual Meeting of the Society of Urologic Oncology/Society for Basic Urologic Research (May 2008)* Society of Urologic Oncology. Meeting, 2009

**society of urologic oncology:** *Proceedings: Annual Meeting of the Society of Urologic Oncology/Society for Basic Urologic Research (May 2007)* Adam S. Kibel, Christopher P. Evans, 2009

**society of urologic oncology: Proceedings of the 2009 Society of Urologic Oncology Annual Spring Meeting** Society of Urologic Oncology. Meeting, 2010

**society of urologic oncology:** *Proceedings* Society of Urologic Oncology, Society for Basic Urologic Research, 2009

**society of urologic oncology: Scientific Information Services of the National Cancer Institute** National Cancer Institute (U.S.), 1987

**society of urologic oncology: Current Catalog** National Library of Medicine (U.S.), 1993  
First multi-year cumulation covers six years: 1965-70.

**society of urologic oncology: IPAB** United States. Congress. House. Committee on Energy and Commerce. Subcommittee on Health, 2012

**society of urologic oncology:** *PDQ User Guide* , 1985

**society of urologic oncology: Journal of the National Cancer Institute** , 2004

**society of urologic oncology: Prostate Cancer For Dummies** Paul H. Lange, Christine Adamec, 2011-03-10  
Hearing that you have prostate cancer, or even that you may have it, is very scary. But this disease, in many cases, is curable. Even if you have advanced cancer that's spread beyond the prostate, many treatments help extend your life for years. You need good information to help you with the decisions that lie ahead, and this book provides you with this information. Prostate Cancer For Dummies can help you if You have prostate cancer (or you think that you have it), or someone close to you has it. You want information on treatments for prostate cancer as you form a treatment plan with your doctor. You are curious about alternative therapies for prostate cancer. You want to know what actions you can take over the long-term to continue to fight your prostate cancer. Prostate Cancer For Dummies explains the key issues and problems that are associated with prostate cancer, and assures you that although the initial impact of being diagnosed is devastating, you can take action to extend your life. You don't have to read this book from the first page straight on through, although you can. You may want to read the first chapter and then move to the chapters that affect you the most. In Prostate Cancer For Dummies, you'll gain insight into Discovering the key symptoms of prostate cancer Recognizing the risk factors, and who's most likely to have prostate cancer Getting a diagnosis, and what's involved Getting well again, and how you can work with your doctor to come up with a plan to cope with your cancer Changing your lifestyle to decrease your risk of a recurrence Coping with the aftermath, from temporary to permanent side effects Handling work and family, and how to help others understand what you're going through It's extremely hard to hear from your doctor that you or a loved one has prostate cancer. But after you recover from the initial shock of diagnosis, you need to educate yourself, and, with the help of your physician, make a plan for getting the best treatment possible. Prostate Cancer For Dummies will help you achieve these goals and encourage you to maintain your commitment to managing your health.

**society of urologic oncology: Proceedings** Society of Urologic Oncology. Midwinter Meeting, 2009

**society of urologic oncology:** *The Remington Registry of Outstanding Professionals* Remington Registry, 2011-04-26

**society of urologic oncology: Scientific Information Services of the National Cancer Institute** National Institutes of Health (U.S.), 1987

**society of urologic oncology: Overactive Bladder in Clinical Practice** Alan J. Wein, Christopher R. Chapple, 2011-12-07  
The book provides a timely and comprehensive update on the overactive bladder (OAB) syndrome. The symptoms of urgency, with or without urge incontinence, usually with frequency or nocturia, now defined as the overactive bladder syndrome, have become a hot topic in urology, gynecology and urogynecology. Epidemiological data show very high disease

prevalence (19%), particularly when compared with other chronic conditions such as diabetes (2%) and asthma (7%). OAB symptoms impact severely on patient's quality of life, causing significant impairment of patient vitality and limiting their physical role, similar to diabetes. The OAB syndrome involves all age groups, both sexes and is frequently found in neurogenic patients. This book will cover all aspects of OAB epidemiology, economics, pathophysiology, conservative, pharmaceutical and surgical and will be invaluable reading for residents and trainees in urology, gynecology and urogynecology.

**society of urologic oncology: The SAGE Encyclopedia of Cancer and Society** Graham A. Colditz, 2015-08-12 The first edition of the Encyclopedia of Cancer and Society was published in 2007 and received a 2008 Editors' Choice Award from Booklist. It served as a general, non-technical resource focusing on cancer from the perspective of the social and behavioral sciences, exploring social and economic impacts, the "business" of cancer, advertising of drugs and treatment centers, how behavior change could offer great potential for cancer prevention, environmental risks, food additives and regulation, the relation between race and ethnicity and cancer risk, socioeconomic status, controversies—both scientific and political—in cancer treatment and research, country-by-country entries on cancer around the world, and more. Given various developments in the field including new drug treatments, political controversies over use of the vaccines Gardasil and Cervarix with young girls to prevent cervical cancer, and unexpected upticks in the prevalence of adult smoking within the U.S. following decades of decline, the SAGE Encyclopedia of Cancer and Society, Second Edition serves as an updated and more current encyclopedia that addresses concerns pertaining to this topic. Key Features: · Approximately half of the 700 first-edition articles revised and updated · 30+ new entries covering new developments since 2006 · Signed entries with cross-references · Further Readings accompanied by pedagogical elements · New Reader's Guide · Updated Chronology, Resource Guide, Glossary, and through new Index The SAGE Encyclopedia of Cancer and Society, Second Edition serves as a reliable and precise source for students and researchers with an interest in social and behavioral sciences and seeks to better understand the continuously evolving subject matter of cancer and society.

**society of urologic oncology: AJCC Cancer Staging Manual** Frederick L. Greene, David L. Page, Irvin D. Fleming, April G. Fritz, Charles M. Balch, Daniel G. Haller, Monica Morrow, 2013-11-21 The American Joint Committee on Cancer's Cancer Staging Manual is used by physicians throughout the world to diagnose cancer and determine the extent to which cancer has progressed. All of the TNM staging information included in this Sixth Edition is uniform between the AJCC (American Joint Committee on Cancer) and the UICC (International Union Against Cancer). In addition to the information found in the Handbook, the Manual provides standardized data forms for each anatomic site, which can be utilized as permanent patient records, enabling clinicians and cancer research scientists to maintain consistency in evaluating the efficacy of diagnosis and treatment. The CD-ROM packaged with each Manual contains printable copies of each of the book's 45 Staging Forms.

**society of urologic oncology: Online Services Reference Manual** , 1988

**society of urologic oncology: Encyclopedia of Cancer and Society** Graham A. Colditz, 2007-09-12 This encyclopedia will define the issues that surround cancer and its effects on society.

**society of urologic oncology: Congressional Record** United States. Congress, 2012

**society of urologic oncology: Scientific Information Services of the National Cancer Institute** National Cancer Institute (U.S.). International Cancer Information Center, 1992

## Related to society of urologic oncology

**OpenWater - Society of Urologic Oncology** Welcome to the Society of Urologic Oncology's abstract portal for the 26th Annual Meeting which will be held December 3 - 5, 2025 in Phoenix, AZ. Abstract categories include:

**Society of Urologic Oncology - Abstract Submission Guidelines** If your abstract is eligible for selection for the Young Urologic Oncologists (YUO) podium session, you will be informed if your

submission (s) has been forwarded for consideration

**Society of Urologic Oncology - PIVOT-006: A Phase 3**, The trial has received Society of Urologic Oncology-Clinical Trials Consortium (SUO-CTC) and Bladder Cancer Advocacy Network (BCAN) support. 90+ clinical sites have been selected

**Society of Urologic Oncology - Application Gallery** Factors Associated with Prostate Cancer Screening among Hispanic Men: Results from Hispanic Community Health Study/Study of Latinos (HCHS/SOL) Presenter: Aysswarya Manoharan

**Society of Urologic Oncology - PHASE 1B UPDATE OF CELLO-1** In preclinical prostate cancer models, TAZ + A/P or TAZ + E led to greater tumor growth reduction than either drug alone. We present an updated analysis of the phase 1b/2 global, open-label,

**Society of Urologic Oncology - CORE-008: A Phase 2, Multi-Arm**, Cretostimogene grenadenorepvec is an oncolytic immunotherapy designed to selectively replicate in bladder cancer cells with Retinoblastoma (Rb)-E2F pathway alterations, commonly found in

**Society of Urologic Oncology - UROLOGIC CANCER DRUG COSTS** A literature search using PubMed was performed to identify costs of urologic cancer medications in LICs, LMICs, UMICs, and HICs. Drug costs were compared in various regions and across

**Society of Urologic Oncology - PENELOPE: TISSUE PENETRATION** Gemcitabine has been used for many years as an intravesical instillation to treat non-muscle invasive bladder cancer (NMIBC). However, due to its short half-life (<3h), each instillation

**Society of Urologic Oncology - Trends in Aborted Radical** Introduction: Radical prostatectomy (RP) is the most commonly performed surgical procedure for men with localized prostate cancer. Typically, patients who are poor surgical candidates are

**Society of Urologic Oncology - ADVANCED-2: PHASE 2 OPEN** TARA-002 is manufactured using the same master cell bank as OK-432, which is approved in Japan and Taiwan for the treatment of several oncology indications. The dose for the Phase 2

**OpenWater - Society of Urologic Oncology** Welcome to the Society of Urologic Oncology's abstract portal for the 26th Annual Meeting which will be held December 3 - 5, 2025 in Phoenix, AZ. Abstract categories include:

**Society of Urologic Oncology - Abstract Submission Guidelines** If your abstract is eligible for selection for the Young Urologic Oncologists (YUO) podium session, you will be informed if your submission (s) has been forwarded for consideration

**Society of Urologic Oncology - PIVOT-006: A Phase 3**, The trial has received Society of Urologic Oncology-Clinical Trials Consortium (SUO-CTC) and Bladder Cancer Advocacy Network (BCAN) support. 90+ clinical sites have been selected

**Society of Urologic Oncology - Application Gallery** Factors Associated with Prostate Cancer Screening among Hispanic Men: Results from Hispanic Community Health Study/Study of Latinos (HCHS/SOL) Presenter: Aysswarya Manoharan

**Society of Urologic Oncology - PHASE 1B UPDATE OF CELLO-1** In preclinical prostate cancer models, TAZ + A/P or TAZ + E led to greater tumor growth reduction than either drug alone. We present an updated analysis of the phase 1b/2 global, open-label,

**Society of Urologic Oncology - CORE-008: A Phase 2, Multi-Arm**, Cretostimogene grenadenorepvec is an oncolytic immunotherapy designed to selectively replicate in bladder cancer cells with Retinoblastoma (Rb)-E2F pathway alterations, commonly found in

**Society of Urologic Oncology - UROLOGIC CANCER DRUG COSTS** A literature search using PubMed was performed to identify costs of urologic cancer medications in LICs, LMICs, UMICs, and HICs. Drug costs were compared in various regions and across

**Society of Urologic Oncology - PENELOPE: TISSUE PENETRATION** Gemcitabine has been used for many years as an intravesical instillation to treat non-muscle invasive bladder cancer (NMIBC). However, due to its short half-life (<3h), each instillation

**Society of Urologic Oncology - Trends in Aborted Radical** Introduction: Radical prostatectomy (RP) is the most commonly performed surgical procedure for men with localized prostate cancer.

Typically, patients who are poor surgical candidates are

**Society of Urologic Oncology - ADVANCED-2: PHASE 2 OPEN** TARA-002 is manufactured using the same master cell bank as OK-432, which is approved in Japan and Taiwan for the treatment of several oncology indications. The dose for the Phase 2

Back to Home: <https://old.rga.ca>